The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column reviews various issues related to the preparation, dispensing, and administration of cancer chemotherapy, both commercially available and investigational.
Get full access to this article
View all access options for this article.
References
1.
FisherB., RedmondC., Legault-PoissonS.Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol.1990; 8: 1005–18.
2.
FisherB., BrownA.M., DimitrovN.V.Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen non-responsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol.1990; 8: 1483–96.
3.
HortobagyiG.N.Treatment of breast cancer. N Engl J Med.1998; 339: 974–84.
4.
National Comprehensive Cancer Network. Update of the NCCN guidelines for treatment of breast cancer. Oncology.1997; 11: 199–220.
5.
HendersonI.C., BerryD., DemetriG.Improved disease-free and overall survival from the addition of sequential pacli-taxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer [abstract]. Proc Am Soc Clin Oncol.1998; 17: 101a.
6.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15: 103–9.
7.
American Society of Health-System Pharmacists.ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health-Syst Pharm.1999; 56: 729–64.
8.
National Comprehensive Cancer Network.NCCN antiemesis practice guidelines. Oncology.1997; 11: 57–89.
9.
StillwellT.J., BensonR.C.Cyclophosphamide-induced hem-orrhagic cystitis, a review of 100 patients. Cancer.1988; 61: 451–7.
American Society of Clinical Oncology.American Society of Clinical Oncology recommendations for the use of hematopoi-etic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol.1994; 12: 2471–2508.
12.
BertelliG.Prevention and management of extravasation of
